Barrett, B, Waheed, W, Farrelly, S et al (2013) Randomised controlled trial of joint crisis plans to reduce compulsory treatment for people with psychosis: economic outcomes. PLoS ONE, 8(11): e74210.
Brazier, J, Ratcliffe, J, Salomon, J et al (2007) Measuring and Valuing Health Benefits for Economic Evaluation. Oxford University Press.
Briggs, A, Claxton, K, Sculpher, M (2006) Decision Modelling for Health Economic Evaluation. Oxford University Press.
Brooks, R (1996) EuroQol: the current state of play. Health Policy, 37: 53–72.
Byford, S, Palmer, S (1998) Common errors and controversies in pharmacoeconomic analyses. PharmacoEconomics, 13: 659–66.
Byford, S, McDaid, D, Sefton, T (2003) Because It's Worth It: A Practical Guide to Conducting Economic Evaluations in the Social Welfare Field. Joseph Rowntree Foundation.
Byford, S, Barrett, B (2010) Ethics and economics: the case for mental heathcare. Advances in Psychiatric Treatment, 16: 468–73.
Byford, S, Barrett, B, Metrebian, N et al (2013) Cost-effectiveness of injectable opioid treatment v. oral methadone for chronic heroin addiction. British Journal of Psychiatry, 203: 341–9.
Claxton, K, Sculpher, M, Palmer, S et al (2015) Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients?
Health Economics, 24: 1–7.
Curtis, L (ed) (2014) PSSRU Unit Costs of Health and Social Care 2014. Personal Social Services Research Unit.
Drummond, M, Jefferson, T (1996) Guidelines for authors and peer reviewers of economic submissions to the BMJ. BMJ, 313: 275–83.
Drummond, M, Sculpher, M, Torrance, G et al (2005) Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press.
Fenwick, E, Byford, S (2005) A guide to cost-effectiveness acceptability curves. British Journal of Psychiatry, 187: 106–8.
Fineberg, NA, Haddad, PM, Carpenter, L et al (2013) The size, burden and cost of disorders of the brain in the UK. Journal of Psychopharmacology, 27: 761–70.
Gold, M, Siegel, J, Russell, L et al (1996) Cost-Effectiveness in Health and Medicine. Oxford University Press.
Guiness, L, Wiseman, V (2011) Introduction to Health Economics (2nd edn). Open University Press.
Jacobs, R (2014) Payment by results for mental health services: economic considerations of case-mix funding. Advances in Psychiatric Treatment, 20: 155–64.
Mauskopf, J, Paul, J, Grant, D et al (1998) The role of cost-consequences analysis in healthcare decision-making. Pharmacoeconomics, 13: 277–88.
McCrone, PR, Dhanasiri, S, Patel, A et al (2008) Paying the Price: The Cost of Mental Health Care in England to 2026. King's Fund.
McIntosh, E, Clarke, P, Frew, E et al (2010) Applied Methods of Cost-Benefit Analysis in Health Care. Oxford University Press.
Mulhern, B, Mukuria, C, Barkham, M et al (2014) Using generic preference-based measures in mental health: psychometric validity of the EQ-5D and SF-6D. British Journal of Psychiatry, 205: 236–43.
National Institute for Health and Care Excellence (2013) Guide to the Methods of Technology Appraisal 2013 (Process and Methods Guides PMG9). NICE.
Norman, I, Coster, S, McCrone, P et al (2010) A comparison of the clinical effectiveness and costs of mental health nurse supplementary prescribing and independent medical prescribing: a post-test control group study. BMC Health Services Research, 10(4).
Petrou, S, Gray, A (2011a) Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting. BMJ, 342: d1548.
Petrou, S, Gray, A (2011b) Economic evaluation using decision analytical modelling: design, conduct, analysis, and reporting. BMJ, 342: d1766.
Ridyard, CH, Hughes, DA (2012) Development of a database of instruments for resource-use measurement: purpose, feasibility, and design. Value in Health, 15: 650–5.
Robinson, R (1993) Economic evaluation and health care: what does it mean?
BMJ, 307: 670–3.
Shanahan, M, Ritter, A (2014) Cost-benefit analysis of two policy options for cannabis: status quo and legalisation. PLoS ONE, 9(4): e95569.
Van Hout, BA, Al, MJ, Gordon, GS et al (1994) Costs, effects and C/E-ratios alongside a clinical trial. Health Economics, 3: 309–19.